The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aciphex     2-[[4-(3-methoxypropoxy)-3- methyl-pyridin...

Synonyms: Pariets, Rabeloc, Eraloc, Habeprazole, rabeprazole, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07864


Psychiatry related information on C07864

  • AIM: To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluoroquinolone, levofloxacin [5].
  • The per protocol eradication rate was significantly better in the 7-day rabeprazole-based therapy and 7-day omeprazole-based therapy groups when compared to the 3-day rabeprazole-based therapy group (P=0.01 and P=0.04, respectively) [6].

High impact information on C07864


Chemical compound and disease context of C07864


Biological context of C07864


Anatomical context of C07864


Associations of C07864 with other chemical compounds


Gene context of C07864

  • The metabolism of rabeprazole is less dependent on CYP2C19 and therefore is the least affected by this genetic polymorphism [23].
  • The inhibitory potency of rabeprazole was relatively lower than the other PPIs, but its thioether analog showed potent inhibition on the P450 enzymes investigated, which may be clinically significant [24].
  • DISCUSSION: Rabeprazole is reduced mainly non-enzymatically to rabeprazole-thioether, which is further stereoselectively re-oxidized by CYP3A4 mainly to (R)-rabeprazole [25].
  • Treatment with rabeprazole almost completely inhibited development of chronic acid reflux esophagitis and significantly decreased expression of cytokines and ICAM-1 mRNA in esophageal tissue compared with control [26].
  • Induction by rabeprazole was significant only for CYP1A1 and CYP1A2, whereas none of the CYP1 mRNAs was induced by pantoprazole [27].

Analytical, diagnostic and therapeutic context of C07864


  1. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Shimatani, T., Inoue, M., Kuroiwa, T., Xu, J., Mieno, H., Nakamura, M., Tazuma, S. Clin. Pharmacol. Ther. (2006) [Pubmed]
  2. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Sugimoto, M., Furuta, T., Shirai, N., Kajimura, M., Hishida, A., Sakurai, M., Ohashi, K., Ishizaki, T. Clin. Pharmacol. Ther. (2004) [Pubmed]
  3. Rabeprazole: an update of its use in acid-related disorders. Carswell, C.I., Goa, K.L. Drugs (2001) [Pubmed]
  4. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Langtry, H.D., Markham, A. Drugs (1999) [Pubmed]
  5. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M.A., Santarelli, L., Arancio, F., Gasbarrini, G. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  6. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Wong, B.C., Wong, W.M., Yee, Y.K., Hung, W.K., Yip, A.W., Szeto, M.L., Li, K.F., Lau, P., Fung, F.M., Tong, T.S., Lai, K.C., Hu, W.H., Yuen, M.F., Hui, C.K., Lam, S.K. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  7. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit? Andrade, R.J., Lucena, M.I. Arch. Intern. Med. (2002) [Pubmed]
  8. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Schneeweiss, S., Maclure, M., Dormuth, C.R., Glynn, R.J., Canning, C., Avorn, J. Clin. Pharmacol. Ther. (2006) [Pubmed]
  9. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Sugimoto, M., Furuta, T., Shirai, N., Nakamura, A., Kajimura, M., Hishida, A., Ohashi, K., Ishizaki, T. Clin. Pharmacol. Ther. (2005) [Pubmed]
  10. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Richardson, P., Hawkey, C.J., Stack, W.A. Drugs (1998) [Pubmed]
  11. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Furuta, T., Shirai, N., Takashima, M., Xiao, F., Hanai, H., Nakagawa, K., Sugimura, H., Ohashi, K., Ishizaki, T. Pharmacogenetics (2001) [Pubmed]
  12. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Stedman, C.A., Barclay, M.L. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  13. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Robinson, M., Horn, J. Drugs (2003) [Pubmed]
  14. Efficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophores. Riel, M.A., Kyle, D.E., Bhattacharjee, A.K., Milhous, W.K. Antimicrob. Agents Chemother. (2002) [Pubmed]
  15. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Horn, J. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  16. The effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled study. Vo, L., Simonian, H.P., Doma, S., Fisher, R.S., Parkman, H.P. Aliment. Pharmacol. Ther. (2005) [Pubmed]
  17. Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells. Yokota, T., Matsui, H., Matsuura, B., Maeyama, K., Onji, M. Eur. J. Pharmacol. (2003) [Pubmed]
  18. Effect of rabeprazole on histamine synthesis in enterochromaffin-like cells of mast cell-deficient (Ws/Ws) rats. Nakamura, S., Watanabe, H., Yokota, T., Matsui, H., Onji, M., Maeyama, K. Eur. J. Pharmacol. (2000) [Pubmed]
  19. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. Setoyama, T., Drijfhout, W.J., van de Merbel, N.C., Humphries, T.J., Hasegawa, J. International journal of clinical pharmacology and therapeutics (2006) [Pubmed]
  20. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Johnstone, D., Berger, C., Fleckman, P. Arch. Intern. Med. (2001) [Pubmed]
  21. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Bruley des Varannes, S., Gharib, H., Bicheler, V., Bost, R., Bonaz, B., Stanescu, L., Delchier, J.C., Bonnot-Marlier, S. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  22. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Warrington, S., Baisley, K., Lee, D., Lomax, K., Delemos, B., Boyce, M., Morocutti, A. Aliment. Pharmacol. Ther. (2007) [Pubmed]
  23. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Ishizaki, T., Horai, Y. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  24. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Li, X.Q., Andersson, T.B., Ahlström, M., Weidolf, L. Drug Metab. Dispos. (2004) [Pubmed]
  25. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Miura, M., Satoh, S., Tada, H., Habuchi, T., Suzuki, T. Eur. J. Clin. Pharmacol. (2006) [Pubmed]
  26. Increased expression of cytokines and adhesion molecules in rat chronic esophagitis. Hamaguchi, M., Fujiwara, Y., Takashima, T., Hayakawa, T., Sasaki, E., Shiba, M., Watanabe, T., Tominaga, K., Oshitani, N., Matsumoto, T., Higuchi, K., Arakawa, T. Digestion (2003) [Pubmed]
  27. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Krusekopf, S., Roots, I., Hildebrandt, A.G., Kleeberg, U. Xenobiotica (2003) [Pubmed]
  28. Rabeprazole. Prakash, A., Faulds, D. Drugs (1998) [Pubmed]
  29. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Homma, M., Itagaki, F., Yuzawa, K., Fukao, K., Kohda, Y. Transplantation (2002) [Pubmed]
  30. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers. Dammann, H.G., Burkhardt, F., Wolf, N. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  31. Seven-day therapy for Helicobacter pylori in the United States. Vakil, N., Lanza, F., Schwartz, H., Barth, J. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  32. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Bytzer, P., Blum, A., De Herdt, D., Dubois, D. Aliment. Pharmacol. Ther. (2004) [Pubmed]
WikiGenes - Universities